Free Trial Information
BioCentury | Mar 28, 2016
Financial News

Atlantic Healthcare completes venture financing

...Business: Autoimmune Date completed: 2016-03-21 Type: Venture financing Raised: $24 million Investors: Fullbrook Thorpe Investments; Lloyds Bank...
Read More
BioCentury | Oct 21, 2013
Financial News

Alliance Pharma completes debt financing

...Neurology, Cardiovascular, Dermatology Date completed: 10/11/13 Type: Debt financing Raised: £25 million ($39.9 million) Investors: Lloyds Bank...
Read More
BioCentury | Feb 15, 2010
Financial News

Alliance Pharma completes private placement

Alliance Pharma plc (LSE:APH), Chippenham, U.K. Business: Neurology, Cardiovascular, Dermatology Date completed: 2/8/10 Type: Private placement Raised: £7.5 million ($11.7 million) Shares: 28.8 million Price: 26p Shares after offering: 222.2 million Placement agent: Numis Securities...
Read More
BioCentury | Aug 24, 2009
Company News

Alliance Pharma, Reckitt Benckiser sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary will acquire worldwide rights to Buccastem prochlorperazine buccal tablets and Timodine hydrocortisone/nystatin/benzalkonium/dimethicone cream from Reckitt Benckiser for £7.5 million ($12.3 million) in cash and stock. Buccastem is marketed in the...
Read More
Items per page:
1 - 4 of 4
BioCentury | Mar 28, 2016
Financial News

Atlantic Healthcare completes venture financing

...Business: Autoimmune Date completed: 2016-03-21 Type: Venture financing Raised: $24 million Investors: Fullbrook Thorpe Investments; Lloyds Bank...
Read More
BioCentury | Oct 21, 2013
Financial News

Alliance Pharma completes debt financing

...Neurology, Cardiovascular, Dermatology Date completed: 10/11/13 Type: Debt financing Raised: £25 million ($39.9 million) Investors: Lloyds Bank...
Read More
BioCentury | Feb 15, 2010
Financial News

Alliance Pharma completes private placement

Alliance Pharma plc (LSE:APH), Chippenham, U.K. Business: Neurology, Cardiovascular, Dermatology Date completed: 2/8/10 Type: Private placement Raised: £7.5 million ($11.7 million) Shares: 28.8 million Price: 26p Shares after offering: 222.2 million Placement agent: Numis Securities...
Read More
BioCentury | Aug 24, 2009
Company News

Alliance Pharma, Reckitt Benckiser sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary will acquire worldwide rights to Buccastem prochlorperazine buccal tablets and Timodine hydrocortisone/nystatin/benzalkonium/dimethicone cream from Reckitt Benckiser for £7.5 million ($12.3 million) in cash and stock. Buccastem is marketed in the...
Read More
Items per page:
1 - 4 of 4